This study involves people living with HIV-1 infection who have not received treatment before. The study will compare different treatment approaches. Some people will receive tablets containing an investigational medicine called VH4524184 (also known as GSK4524184) together with a combination of two approved medicines, emtricitabine and tenofovir alafenamide, which are given as a single tablet called Descovy. Other people will receive a different approved combination treatment called Dovato, which contains lamivudine and dolutegravir sodium. All medicines in this study are taken by mouth. These medicines belong to a group called antiretroviral treatments, which work to control the virus in the body.
The purpose of this study is to find out how well the investigational treatment containing VH4524184 works in reducing the amount of virus in the blood compared to the approved treatment, and to check how safe these treatments are. The study will look at whether the amount of virus in the blood drops to very low levels and stays low during the treatment period. The study will also measure changes in certain blood cells that are important for the immune system and will check for any side effects that may occur during treatment.
People who join this study will be assigned to receive one of the treatment combinations and will take their assigned medicine for up to 24 months. During this time, they will have regular visits where blood samples will be collected to measure the amount of virus in the blood and to check their overall health. The study will monitor how well the treatment works and how people respond to it over time. The study is expected to start in early 2026 and continue until late 2028.
Belgium 
France 
Germany 
Italy 
Poland 
Portugal 
Spain 